First Eagle Investment Management LLC Buys 43,100 Shares of Surgery Partners, Inc. (NASDAQ:SGRY)

First Eagle Investment Management LLC increased its stake in shares of Surgery Partners, Inc. (NASDAQ:SGRY) by 17.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 292,278 shares of the company’s stock after acquiring an additional 43,100 shares during the quarter. First Eagle Investment Management LLC’s holdings in Surgery Partners were worth $6,188,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Raymond James Financial Inc. bought a new stake in Surgery Partners in the 4th quarter valued at $10,130,000. Charles Schwab Investment Management Inc. boosted its stake in shares of Surgery Partners by 8.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 834,417 shares of the company’s stock valued at $17,665,000 after purchasing an additional 61,671 shares in the last quarter. NINE MASTS CAPITAL Ltd acquired a new stake in shares of Surgery Partners in the 4th quarter valued at $606,000. Versor Investments LP boosted its stake in shares of Surgery Partners by 450.0% in the 4th quarter. Versor Investments LP now owns 46,200 shares of the company’s stock valued at $978,000 after purchasing an additional 37,800 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of Surgery Partners by 17.7% in the 4th quarter. Bank of New York Mellon Corp now owns 340,776 shares of the company’s stock valued at $7,214,000 after purchasing an additional 51,187 shares in the last quarter.

Insiders Place Their Bets

In related news, CFO David T. Doherty sold 6,733 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $24.02, for a total transaction of $161,726.66. Following the transaction, the chief financial officer now directly owns 150,868 shares in the company, valued at $3,623,849.36. This trade represents a 4.27 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Marissa Brittenham sold 3,156 shares of Surgery Partners stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $24.09, for a total value of $76,028.04. Following the completion of the sale, the insider now owns 63,408 shares in the company, valued at approximately $1,527,498.72. This represents a 4.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 106,622 shares of company stock worth $2,717,860 in the last quarter. 2.30% of the stock is owned by company insiders.

Surgery Partners Trading Down 0.0 %

NASDAQ:SGRY opened at $23.60 on Friday. The company has a quick ratio of 1.66, a current ratio of 1.80 and a debt-to-equity ratio of 0.99. The company has a market cap of $3.01 billion, a P/E ratio of -49.17, a price-to-earnings-growth ratio of 19.21 and a beta of 2.73. The business has a 50 day moving average price of $23.58 and a two-hundred day moving average price of $26.04. Surgery Partners, Inc. has a twelve month low of $19.50 and a twelve month high of $33.97.

Surgery Partners (NASDAQ:SGRY) last issued its earnings results on Monday, March 3rd. The company reported $0.39 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.01. The company had revenue of $864.40 million for the quarter, compared to analyst estimates of $828.09 million. Surgery Partners had a positive return on equity of 2.85% and a negative net margin of 2.03%. As a group, analysts expect that Surgery Partners, Inc. will post 0.67 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently commented on SGRY. Royal Bank of Canada reduced their target price on shares of Surgery Partners from $49.00 to $35.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 20th. JPMorgan Chase & Co. reduced their price target on shares of Surgery Partners from $38.00 to $28.00 and set a “neutral” rating on the stock in a research report on Tuesday, December 3rd. Macquarie reduced their price target on shares of Surgery Partners from $34.00 to $33.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 11th. Finally, Bank of America began coverage on shares of Surgery Partners in a research report on Monday, December 16th. They set a “buy” rating and a $30.00 price target on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $36.63.

Surgery Partners Company Profile

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.